基于miRNA和组织特异性预测复杂疾病的潜在治疗
Predicting potential treatments for complex diseases based on miRNA and tissue specificity
摘要:
药物重新定位,即为现有药物寻找新的用途,以治疗更多的患者。大量研究表明成熟的miRNAs及其前体可以被小分子药物靶向。与此同时,人类疾病是由组织和细胞谱系特异性过程的无序相互作用造成的。然而,很少有计算研究预测基于miRNA数据和组织特异性的药物-疾病的潜在关系。因此,基于miRNA数据和疾病的组织特异性,我们提出了一种名为miTS的新方法来预测疾病的潜在治疗方法。首先,基于miRNA数据、靶基因和FDA批准的药物信息,我们评估了组织特异性PPI网络中miRNA和药物之间的关系。最后,我们构建了一个三方网络:药物-miRNA-疾病。在本文中,我们以乳腺癌为案例研究,重点关注前30名预测药物。其中25种药物(83.3%)在CTD基准中被发现与乳腺癌有已知的联系,另外5种药物是治疗乳腺癌的潜在药物。我们进一步从临床记录、文献挖掘、KEGG途径富集分析和富集途径之间的重叠基因来评估5种新预测的药物。对于这5种新药,每一种都可以在三个或更多方面找到强有力的支持证据。特别是,瑞格非尼与乳腺癌有15个重叠的KEGG通路,它们的p值都很小。此外,无论是在文献整理还是临床验证中,瑞戈非尼与乳腺癌都有很强的相关性。所有的事实表明,瑞格非尼很可能是一种真正有效的药物,值得我们进一步研究。因此,我们的方法miTS是有效和实用的预测新药适应症。
英文摘要:
Drug repositioning, that is finding new uses for existing drugs to treat more patients. Cumulative studies demonstrate that the mature miRNAs as well as their precursors can be targeted by small molecular drugs. At the same time, human diseases result from the disordered interplay of tissue- and cell lineage-specific processes. However, few computational researches predict drug-disease potential relationships based on miRNA data and tissue specificity. Therefore, based on miRNA data and the tissue specificity of diseases, we propose a new method named as miTS to predict the potential treatments for diseases. Firstly, based on miRNAs data, target genes and information of FDA approved drugs, we evaluate the relationships between miRNAs and drugs in the tissue-specific PPI network. Then, we construct a tripartite network: drug-miRNA-disease Finally, we obtain the potential drug-disease associations based on the tripartite network. In this paper, we take breast cancer as case study and focus on the top-30 predicted drugs. 25 of them (83.3%) are found having known connections with breast cancer in CTD benchmark and the other 5 drugs are potential drugs for breast cancer. We further evaluate the 5 newly predicted drugs from clinical records, literature mining, KEGG pathways enrichment analysis and overlapping genes between enriched pathways. For each of the 5 new drugs, strongly supported evidences can be found in three or more aspects. In particular, Regorafenib has 15 overlapping KEGG pathways with breast cancer and their p-values are all very small. In addition, whether in the literature curation or clinical validation, Regorafenib has a strong correlation with breast cancer. All the facts show that Regorafenib is likely to be a truly effective drug, worthy of our further study. It further follows that our method miTS is effective and practical for predicting new drug indications.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。